ISMICS 2025 Annual Meeting

OBJECTIVE:

In many centers, minimally invasive technique is an accepted approach for mitral valve surgery. In our center we have adopted endoaortic ballon occlusion (Intraclude™, Edwards Lifesciences) as the preferred method for aortic cross clamping.

METHODS:

This is a single-centre, one surgeon, retrospective analysis of the use of endodontic balloon occluder in endoscopic mitral valve surgery at Blackpool Victoria Hospital between June 2009 till August 2024.

Patients underwent isolated endoscopic mitral valve surgery have been included. The exclusion criteria were: aortic regurgitation , peripheral arterial disease , aortic aneurysm and concomitant valve surgery. The outcome measures were evaluated: bypass and clamp time, ICU and hospital stay, and major adverse cardiac and cerebrovascular events (MACCE).

RESULTS:

A total of 458 patients (167 females and 291 males), age between 20 to 92 years (mean age: 63yrs) underwent endoscopic mitral valve surgery were included in the study.

368 patients had Mitral repair while 90 patients had mitral valve replacement

•Mean EuroScore II was 1.36.

•The mean cardiopulmonary bypass and the mean aortic cross-clamp time were 168 min and 114 min respectively.

•There were no intraoperative complications reported. The length of ICU Stay was (24hours), total hospital stay was 7 days (mean 2-103days).

•Post operative complications reported were :

o11 patients (2.4%) returned to the theatre for re-exploration ,

o4 patients (0.9%) required postop Hemofiltration/Dialysis.

o2 patients (0.4%) had postoperative stroke.

One in-hospital mortality (0.2 %).

CONCLUSIONS:

Our findings unequivocally demonstrate the safety of EABO in endoscopic mitral valve surgery.

ISMICS 2025 Annual Meeting

Outcome Of Endoaortic Balloon Occlusion In Endoscopic Mitral Surgery

Poster Presenter

Authors

Affiliations

Part of Topic